Forma Stanzolhas a fresh new look, a new pump, and an improved, more potent formula with 10% more Forma Stanzol per bottle all at the same price.
Burn fat, inhibit aromatase, build muscle, and recover better with Forma Stanzol. The revolutionary transdermal anti-estrogen needed for every steroid cycle and Post Cycle Therapy (PCT).
Forma Stanzol really is an amazing anti-estrogen lotion that should be a part of EVERY cycle and Post Cycle Therapy, not only for muscle gains and fat loss, but for longevity and health for any bodybuilder. Forma Stanzol’s primary ingredient is one of the world”s most potent aromatase inhibitors, known as cyclohexylaminoglutethimide (3-(4-aminophenyl)-3-cyclohexylpiperidine-2,6-dione).
Cyclohexylaminoglutethimide is a highly potent nonsteroidal, non-suppressive, selective aromatase inhibitor that is more potent than our original ingredient, Formestane. That’s right! Cyclohexylaminoglutethimide is more effective at inhibiting aromatase than Formestane. But one of the great things about Forma Stanzol is that with the transdermal delivery system, you can pump out as little or as much lotion as you need to meet your individual dose requirement.
This already highly effective drug with very low toxicity concerns is made more effective and even safer due to advancements in transdermal delivery systems. Bottom line…Forma Stanzol is back and thanks to the innovators at Muscle Research, it is more powerful than ever. The improved and more potent Forma Stanzol increases IGF-1 levels by an amazing 27%!
Now you can understand why Muscle Research and many other professionals in the bodybuilding community recommend Forma Stanzol to be a part of any and every cycle and PCT from this day forward. Whether it”s to keep your estrogen under control, prevent deca and tren libido problems, recover your HPTA from a cycle or to simply help create a more anabolic friendly environment better suited for muscular gains and fat loss…Forma Stanzol is your #1 choice.
Forma Stanzol is the best non-prescription aromatase inhibitor on the market. It works just like other AI’s (such as Arimidex, Femara, Aromasin, etc.) but at a fraction of the cost. If one wanted to prevent gynecomastia (aka. gyno, man boobs) and other cycle side effects they may need 2 or 3 different drugs. Of course each one of these drugs comes with its own set of negative side effects. Some AI”s raise SHBG, some lower IGF-1 and too much of any of them may leave you feeling weak and brittle.
No returns can be accepted for this item. It is not tamper proof sealed and we cannot re-sell it.
What results can I expect from Forma Stanzol?
Forma Stanzol inhibits aromatase by as much as 95-98%, which helps prevent excess fat storage and gynecomastia (male breast development) as well as potentially reducing incidences of estrogen related cancers.
Forma Stanzol can increase IGF-1 levels by as much as 27%. Doing so creates the perfect anabolic muscle building environment on cycle, off cycle and during pct.
Forma Stanzol decreases the activity of progesterone (inhibits the trenbolone and “deca-dick” type side effects).
Why is it Important to Inhibit Aromatase Production?
The male body uses an enzyme called aromatase to convert a percentage of susceptible androgens into estrogens. Naturally this includes both those that the body produces and those introduced from outside the body such as AAS (Anabolic Androgenic Steroids). In most cases the result is predominantly a very powerful and potentially fatal estrogen called estradiol.
Aromatase is present in most body tissues and the circulatory system. Unfortunately fat cells produce a scary amount of this man-altering enzyme…which of course explains why fat guys get boobs.
When we think of aromatase inhibitors we often assume that they are all the same with various levels of results…depending upon dosages. While the latter may be true, the prior statement certainly is not.
Aromatase Inhibitor “Types”?
Let’s do a quick review of the types of aromatase inhibitors that are available, including the improved Forma Stanzol. These include type 1, or steroidal inactivators, and type 2, or nonsteroidal inhibitors. The type 1 aromatase inhibitors include exemestane and formestane and are actually very weak androgen analogues. The type 2 inhibitors include cyclohexylaminoglutethimide, anastrozole, letrozole, and vorozole.
There are both similarities and differences between the type 1 and 2 aromatase inhibitors. Their similarities include the fact that both inhibit aromatase in a very specific fashion and reduce endogenous or circulating estrogens. The steroidal inhibitors bind to the aromatase molecule in an irreversible fashion (they hold on and do not let go). But because aromatase is rapidly replaced within the body, studies done on comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior. In addition, the steroidal AI’s have a structure similar to that of androgens and may, usually in very high doses, have weak anabolic steroid or androgen-type properties, which may not be desirable nor necessary, especially in PCT. After all, Forma Stanzol is an Aromatase Inhibitor, not a steroid. It is commonly used in conjunction with steroids to help prevent negative steroid side effects, and in PCT, after a cycle of anabolic steroids, to aid HPTA recovery and prevent estrogen rebounds.
Of the type 1 agents, exemestane is considerably more potent than formestane. Of the type 2 agents, letrozole tends to be the most potent in regards to estrogen suppression. In fact, users often complain that letrozole is too suppressive, leading to weakness, achy joints and sometimes injury. But again in each case this may be dose dependent more so than a question of effectiveness of the drug itself. In vivo (tested in live subjects rather than a test tube), the aromatase inhibitors can be graded as shown in the basic table shown above.
While this table may make Letrozole out to be the winner in overall aromatase inhibition, remember, we don’t want to completely destroy estrogen. You read that right! Even men need some estrogen to maintain a healthy, balanced endocrine system. On cycle and off…Forma Stanzol is the clear cut winner when it comes to balancing hormones with the least potential side effects.
Anti-Estrogens and IGF-1 Production
GH (Growth Hormone) is like a master hormone for tissue growth and fat regulation due to its own intrinsic qualities and its propensity to be converted into or trigger the production and release of Growth Factors. Of these Growth Factors, one of the best known in regard to muscle growth is IGF-1 (Insulin-Like Growth Factor-1).
As most are aware by now, IGF-1 is a powerful anabolic and anti-catabolic hormone. Whether in pre-contest mode or packing on the mass, the amount of circulating and stored IGF-1 an athlete maintains plays a powerful role in the results achieved. Obviously as IGF-1 levels decrease so does the potential for packing on the beef, and the amount of lean tissue lost during calorie-restricted periods increases as well (not good).
Estrogen, and more so estradiol, can trigger GH release from the pituitary gland. Aromatase inhibitors decrease the amount of circulating estrogen/estradiol and estrogen receptor antagonist keep estrogen out of the specific pituitary receptors. So in many regards the use of anti-estrogens can effect IGF-1 production and in some cases affect the number of IGF-1 receptors our tissues possess.
Why should I choose Forma Stanzol as my AI?
Forma Stanzol increases IGF-1 secretion and activity.
Forma Stanzol decreases the activity of progesterone (inhibits the trenbolone and “deca-dick” type side effects).
Forma Stanzol inhibits 95-98% of aromatase enzyme activity.
Forma Stanzol increases HPTA activity similar to HCG and Clomid together.
Forma Stanzol inhibits DHT (dehydrotestosterone) activity.
Forma Stanzol decreases prostate concerns such as BPH.
Forma Stanzol increases testosterone.
What is in Forma Stanzol?
Each bottle contains aproxemately 132 pumps
2 pumps contain:
7,8 – Benzoflavone (99%) 25mg
Horse Chestnut seed extract 8mg
Suggested use of Forma Stanzol
Forma Stanzol is a transdermal lotion that is applied by rubbing on your skin.
1. On cycle estrogen and progesterone control: Apply 1-2 pumps twice daily for up to 10 weeks to upper back, shoulders, arms and abdomen. Strength of effects are dose dependent. Start off with a lighter dose and work up as needed.
2. Stand alone Anabolic fat burning agent: Apply 1-2 pumps twice daily for 4-6 weeks to upper back, shoulders, arms and abdomen. Strength of effects are dose dependent. Start off with a lighter dose and work up as needed.
3. For post cycle therapy: Apply 1-2 pumps twice daily for 4-6 weeks to upper back, shoulders, arms and upper abdomen. Strength of effects are dose dependent. Start off with a lighter dose and work up as needed.
Synthesis and aromatase inhibition of 3-cycloalkyl-substituted 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1992 Jun 12;35(12):2210-4.
Aromatase inhibitors in men: effects and therapeutic options. Reproductive Biology and Endocrinology 2011, 9:93 doi:10.1186/1477-7827-9-93
Evaluation of the racemate and the enantiomers of a new highly active and selective aromatase inhibitor of the aminoglutethimide type. J Steroid Biochem Mol Biol. 1992 Dec;43(7):641-8.
Vibrational spectroscopy of cyclohexylaminoglutethimide in low-temperature matrices, solutions and the solid state. Journal of Molecular Structure 560 (2001) 137±149
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996 Jun;81(6):2216-21
Effects of Aromatase Inhibitors, Aminoglutethimide, and 4-Hydroxyandrostenedione on Cyclic Rats and Rats with 7,12-Dimethylbenz(a)anthracene-induced Mammary Tumors1CANCER RESEARCH 45, 2425-2428, June 1985
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest. 1980 Mar;65(3):602-12.
Inhibition of human placental progesterone synthesis by aminoglutethimide in vitro. Int J Biol Res Pregnancy. 1982;3(4):167-72.
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial. J Clin Oncol. 2013 Apr 10;31(11):1398-404. doi: 10.1200/JCO.2012.44.7805. Epub 2013 Jan 28.
Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257-65.
In Vivo and in Vitro Pharmacological Studies of Aminoglutethimide as an Aromatase Inhibitor CANCER RESEARCH (SUPPL.) 42, 3353s-3359s, August1982
Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450arom). J Enzyme Inhib. 1995;9(3):195-202.
First generation aromatase inhibitors–aminoglutethimide and testololactone. Breast Cancer Res Treat. 1994;30(1):57-80.
Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer. Breast Cancer Res Treat 1994;30(2):127-32
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 1997 Nov-Dec;63(4-6):261-7
The luteinizing hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. J Steroid Biochem Mol Biol 2000 Dec 1;75(1):65-73
Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000 Jul;85(7):2370-7 Nemours Research Programs at the Nemours Children”s Clinic, Jacksonville, Florida 32207, USA.
Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 1999 Apr;35(4):596-600 FIRC Chemoprevention Unit, European Institute of Oncology, Milan, Italy.
Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI Lady Davis Research Institute, and Department of Medicine, McGill University, 3755 Cote St. Catherine Road, Montreal, Quebec H3T 1E2, Canada. Clin Cancer Res 1996 Dec;2(12):2037-42
Davies JH et al. Effects of 4-hydroxyandrost-4-ene-3,17-dione and its metabolites on 5 alpha-reductase activity and the androgen receptor. J Enzyme Inhib. 1992;6(2):141-7.
KEEP OUT OF REACH OF CHILDREN. This product is intended for adults only. Not for use for anyone under 18 years of age, pregnant or nursing women. If you have had a medical condition or are currently using prescription drugs consult your physician before using this product. Avoid this product if you have any previous history of medical dysfunction or disease including but not limited to kidney disease. Discontinue use and consult your doctor if any adverse reactions occur.
“These statements have not been evaluated by the Food & Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. ALWAYS consult your physician before use.”